Notice of Intent to Publish a Notice of Funding Opportunity for Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)
ID: 357910Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357910
Timeline
    Description

    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the Alzheimer’s Clinical Trials Consortium (ACTC) aimed at developing and implementing multi-site Phase Ib to III clinical trials for interventions targeting Alzheimer’s disease (AD) and related dementias (ADRD). This initiative seeks applications for promising pharmacological and non-pharmacological strategies that may prevent, delay, or treat the symptoms of AD, utilizing the ACTC's trial coordination and management infrastructure. The NOFO is significant as it addresses a critical health challenge, and it is expected to be published in December 2024, with application due dates in March, June, and October of 2025. Interested applicants should prepare for the R01 activity code funding, with an estimated award date set for December 1, 2025.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Alzheimer's Clinical Trials Consortium (ACTC) aimed at developing and implementing multi-site Phase Ib to III clinical trials for interventions targeting Alzheimer's disease (AD) and related dementias (ADRD). This initiative seeks to foster collaborative efforts between applicants, the National Institute on Aging (NIA), and the ACTC network to test promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat symptoms associated with AD and ADRD. The funding opportunity, utilizing the R01 activity code, is particularly significant as it addresses the growing need for effective treatments for age-related cognitive decline. Interested small businesses are encouraged to prepare for application submission, with the estimated synopsis post date on August 1, 2025, and a closing date of October 5, 2025. For further inquiries, potential applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting early- and late-stage clinical trials focused on Alzheimer's Disease (AD), Alzheimer's Disease-Related Dementias (ADRD), and age-related cognitive decline. This initiative seeks applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive, behavioral, and neuropsychiatric changes associated with these conditions, as well as studies to enhance trial design and methodologies. The funding opportunity, categorized under health-related discretionary grants, is intended for small businesses with expertise in aging research, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 5, 2025. For further inquiries, interested applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    AD/ADRD Clinical Trials Short Course
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the AD/ADRD Clinical Trials Short Course aimed at enhancing the workforce skilled in Alzheimer's disease (AD) and AD-related dementias (ADRD) clinical trials. This initiative seeks to develop innovative short courses that will train the next generation of clinical trialists in advanced research skills pertinent to AD, frontotemporal dementia (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and mixed dementia, as well as interventions for treatment and prevention. While applications are not currently being solicited, potential applicants are encouraged to begin forming collaborations and project ideas in anticipation of the funding opportunity, which will utilize the R25 activity code. For further inquiries, interested parties can contact Laurie Ryan at the National Institute on Aging via email at ryanl@mail.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is September 1, 2025, with a closing date for applications expected by January 25, 2026, and an anticipated award date of December 1, 2026.
    National Alzheimer’s Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the establishment of a National Alzheimer's Coordinating Center (NACC) under a cooperative agreement. The NACC aims to serve as a national data resource for Alzheimer's disease and related dementias (AD/ADRD) research, facilitating data collection from Alzheimer’s Disease Research Centers (ADRCs) and enhancing communication within the ADRC program. This initiative is crucial for advancing research in the field of aging and dementia, providing a centralized hub for collaboration and data sharing. Interested small businesses are encouraged to prepare for the application process, with the estimated synopsis posting date on August 15, 2025, and the anticipated award date set for July 15, 2026. For further inquiries, potential applicants can contact Dr. Cerise Elliott at elliottce@nih.gov or by phone at 301-496-9350.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Notice of Intent to Publish a Notice of Funding Opportunity for Centers on the Demography and Economics of Aging and Alzheimer�s Disease and Alzheimer�s Disease Related Dementias Coordinating Center (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the establishment of a Coordinating Center focused on the Demography and Economics of Aging, including Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD). The objective of this cooperative agreement is to create a hub that facilitates collaboration among various D&E Centers, scholars, and the research community, enhancing the scientific impact and fostering synergies across related programs and infrastructures. This initiative is crucial for promoting an inclusive research environment and raising awareness about the demography and economics of aging. The estimated total program funding is $1,320,000, with an award ceiling of $800,000, and the application process is expected to open in July 2024, with submissions due by October 2024. Interested applicants should prepare to develop meaningful collaborations in advance of the application deadline.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.